PD28 Cost-Effectiveness Of Selective Internal Radiation Therapy Using Y-90 Resin Microspheres For Unresectable Hepatocellular Carcinoma In Brazil

IntroductionHepatocellular cancer (HCC) is a severe condition with poor prognosis and a significant burden. Selective internal radiation therapy (SIRT) is recommended as an alternative treatment option to overcome some limitations of current treatments. This analysis estimated the cost-effectiveness of SIRT using Y-90 resin microspheres for the treatment of unresectable HCC in Brazil.MethodsThis study was conducted from the Brazilian payer perspective according to local guidelines, with a lifetime horizon. The use of SIRT in patients with intermediate- or advanced-stage HCC, without extrahepatic disease and ineligible to transarterial chemoembolization, was compared with sorafenib, the commonly used HCC systemic treatment in Brazil. A sensitivity analysis included the subgroup of patients with low tumour burden and preserved liver function.A partitioned-survival model was developed, which included a tunnel state for patients downstaged to receive a treatment with a curative intent such as liver surgery, transplantation or ablation. Survival curves, utilities and adverse events incidence were extracted from published sources of pivotal randomized control trials. Effectiveness of health interventions was measured in quality-adjusted-life-years (QALYs) and life-years (LYs). Local costs from Brazil were applied. Future costs and effects were discounted at five percent. A willingness-to-pay threshold of USD 53,936 was used, based on a 2017 review of healthcare technology adoption in Brazil.ResultsLYs and QALYs were higher for SIRT using Y-90 resin microspheres versus sorafenib (0.27 and 0.20 incremental LYs and QALYs, respectively) and costs were slightly higher for SIRT (USD 3,056 incremental costs). The incremental cost-effectiveness ratio (ICER) was USD 14,948 per QALY in the basecase.One-way and probabilistic sensitivity analyses confirmed the robustness of the analyses. Scenario analyses tested different model assumptions and reinforced the basecase results indicating that SIRT using Y-90 resin microspheres was highly likely to be cost-effective compared with sorafenib. Also, the ICER was lower in the subgroup compared with the overall population.ConclusionsSIRT using Y-90 resin microspheres represents a cost-effective option compared with sorafenib in Brazil.